Probi publishes annual report for 2017
Probi's Annual Report for 2017 is now available on the company website, www.probi.com under Investor Relations. Distribution of the printed annual report will start during week 16 to shareholders who subscribe to our financial reporting.
This information is information that Probi AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 8.30 CET on 29 March 2018.
FOR FURTHER INFORMATION, CONTACT:
Niklas Brandt, CIO & Investor relations, Probi, tel +46 46 286 89 26, e-mail: firstname.lastname@example.org
Probi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2017, Probi had net sales of MSEK 612. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. Read more at www.probi.com.